Page not found

Neuroscience PhD at Wake Forest University at Wake Forest University

Wake Forest University Graduate School » Neuroscience PhD at Wake Forest University

Waldemar Debinski

Waldemar Debinski
Education & Training
  MD Academy Med Warsaw-Poland 1981
  PhD Mcgill University Med-Canada 1989


Debinski W, Wykosky J, Gibo D, inventors; Wake Forest University Health Sciences, assignee. Molecular signature of cancer. United States patent US 8,343,461. 2013 Jan 1. 2013;():.


Debinski W, Pandya H, Gibo D, inventors; Wake Forest University Health Sciences, assignee. Multi-level specific targeting of cancer cells. United States patent US 8,362,207. 2013 Jan 29. 2013;():.


Ferluga S, Hantgan R, Goldgur Y, Himanen JP, Nikolov DB, Debinski W. Biological and structural characterization of glycosylation on Ephrin-A1, a preferred ligand for EphA2 receptor tyrosine kinase. J Biol Chem. 2013;288(25):18448-57.


Pandya H, Gibo DM, Garg S, Kridel S, Debinski W. An interleukin 13 receptor alpha 2-specific peptide homes to human glioblastoma multiforme xenografts. Neuro Oncol. 2012;14(1):6-18.


Beauchamp A, Debinski W. Ephs and ephrins in cancer: ephrin-A1 signalling. Semin Cell Dev Biol. 2012;23(1):109-115.


Lema Tome CM, Palma E, Ferlaga S, Lowther WT, Hantgan R, Wykosky J, Debinski W. Structural and functional characterization of monomeric EphrinA1 binding site to EphA2 receptor. J Biol Chem. 2012;287(17):14012-22.


Garcia-Espinosa MA, Lesser GJ, Debinski W, Tallant EA, Gallagher PE.Angiotensin-(1-7), a peptide hormone with therapeutic potential for the treatment of glioblastomas [abstract]. In: Proceedings of the 103rd Annual Meeting of the Amerian Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, Illinois. Philadelphia (PA): AACR. 2012;():Abstr 1938.



Beauchamp A, Lively MO, Mintz A, Gibo D, Wykosky J, Debinski W. EphrinA1 is released in three forms from cancer cells by matrix metalloproteases. Mol Cell Biol. 2012;32(16):3253-3264.


Nguyen V, Conyers JM, Zhu D, Gibo DM, Hantgan RR, Larson SM, Debinski W, Mintz A. A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13R alpha2 tumor-restricted biomarker. Neuro Oncol. 2012;14(10):1239-1253.


Debinski W, Gonzales O, Beauchamp A, Gibo DM, Seals DF. Epha2/Ephrina1 system in conjunction with TKS5 regulates invadopodia formation in glioblastoma cells [abstract]. Neuro Oncol. 2012;14(Suppl 6):14.


Ferluga S, Debinski W. Glycosylation is critical for Ephrina1 production and Epha2 activation [abstract]. Neuro Oncol. 2012;14(Suppl 6):15.


Gibo DM, Dickinson P, Robertson J, Rossmeisl J, Debinski W. Highly potent cytotoxin targeting Il-13R alpha 2 in canine and human glioblastoma [abstract]. Neuro Oncol. 2012;14(Suppl 6):31-32.


Gibo DM, Debinski W, Bonomo J, Rossmeisl J, Robertson J, Dickinson P.Interleukin 13 receptor alpha-2 is widely over-expressed in human and canine primary brain tumors as detected by novel bispecies-specific monoclonal antibodies [abstract]. Neuro Oncol. 2012;14(Suppl 6):47.


Seals DF, Burger KL, Gibo DM, Debinski W. The role of proto-oncogenes in tumor-associated macrophage polarization and promotion of GBM tumor progression [abstract]. Neuro Oncol. 2012;14(Suppl 6):3.


Lema Tome CM, Miller LD, Debinski W. Molecular and genetic features of highly migratory glioblastoma cells [abstract]. Neuro Oncol. 2012;14(Suppl 6):162.


Debinski W, Gibo DM. Fos-related antigen 1 (Fra-1) pairing with and transactivation of JunB in GBM cells. Cancer Biol Ther. 2011;11(2):254-262.


Nguyen V, Conyers JM, Zhu D, Gibo DM, Dorsey JF, Debinski W, Mintz A. IL-13R alpha2-targeted therapy escapees: biologic and therapeutic implications. Transl Oncol. 2011;4(6):390-400.


Pandya H, Gibo DM, Debinski W. Molecular targeting of intracellular compartments specifically in cancer cells. Genes Cancer. 2010;1(5):421-433.


Candolfi M, Xiong W, Yagiz K, Liu C, Muhammad AKMG, Puntel M, Foulad D, Zadmehr A, Ahlzadeh GE, Debinski W, et al. Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. Proc Natl Acad Sci U S A. 2010;107(46):20021-6.



Beauchamp AS, Gibo DM, Wykosky J, Debinski W. Elucidation of the release and function of monomeric ephrina1 in glioblastoma multiforme [abstract]. Neuro Oncol. 2010;12(Suppl 4):22.


Pandya H, Gibo D, Debinski W. Development of multiple-specificity vectors for targeted delivery to intracellular compartments of GBM cells [abstract]. Neuro Oncol. 2010;12(Suppl 4):89.


Lema Tome CM, Wykosky J, Palma E, Debinski W. Functional and structural characterization of the high-affinity EphA2-binding site of ephrinA1 [abstract]. Neuro Oncol. 2010;12(Suppl 4):92.


Nguyen V, Murphy LT, Beauchamp AS, Hollingsworth CK, Debinski W, Mintz A.Combinatorial targeting of EphA2 and IL-13Ralpha2 GBM-restricted biomarkers [abstract]. Neuro Oncol. 2010;12(Suppl 4):97.



Tanaka ML, Debinski W, Puri IK. Hybrid mathematical model of glioma progression. Cell Prolif. 2009;42(5):637-646.


Debinski W, Tatter SB. Convection-enhanced delivery for the treatment of brain tumors. Expert Rev Neurother. 2009;9(10):1519-1527.


Debinski W, Garg S, Gibo DM, Kridel S, Pandya H. Isolation and characterization of interleukin 13 receptor alpha2-specific heptapeptides [abstract]. Neuro Oncol. 2009;11(6):898.


Debinski W, Dickinson P, Gibo DM. Novel monoclonal antibody 13R2.C3 against iinterleukin [sic] 13 receptor alpha-2 reveals a specific and more widespread expression of the receptor in various brain tumors [abstract]. Neuro Oncol. 2009;11(6):963.